My Treatment Approach Beyond the First-Line: Expert Insights on Evidence-Driven TKI Selection and Sequencing in Advanced GIST - Episode 7

ctDNA Biomarkers in INTRIGUE: Understanding Resistance Patterns

April 21, 2025

Breelyn Wilky, MD, Jason Sicklick, MD, FACS, Seth M. Pollack, MD

Experts discuss the key insights from the follow-up exploratory analysis of the INTRIGUE trial investigating circulating DNA (ctDNA) biomarkers and how mutation-specific findings may influence molecular testing before selecting a second-line agent, with practical implications for implementing a more personalized approach in clinical practice.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Optimizing TKI Selection and Sequencing Strategies in Advanced GIST Beyond First-Line Therapy

EP. 2: Biological Mechanisms of GIST Resistance and Tumor Heterogeneity

EP. 3: Monitoring Tumor Heterogeneity and Detecting Resistance

EP. 4: Post-Imatinib Progression: Decision Factors and Treatment Options

EP. 5: INVICTUS Trial: Ripretinib in Fourth-Line Setting

EP. 6: INTRIGUE Trial: Key Findings in Second-Line Setting

Now Viewing

EP. 7: ctDNA Biomarkers in INTRIGUE: Understanding Resistance Patterns

EP. 8: Managing Adverse Events With Different TKIs

EP. 9: Next-Generation Treatment Strategies for GIST: Evaluating Combination Therapies and Mutation-Specific Approaches

EP. 10: Practical Recommendations for Community Oncologists

Video content above is prompted by the following:

A follow-up exploratory analysis of the INTRIGUE trial investigated ctDNA biomarkers to better understand resistance patterns. Could you discuss the key insights from this analysis? How might these mutation-specific findings change our approach to molecular testing before selecting a second-line agent, and what are the practical implications for implementing this more personalized approach in clinical practice?